Study S000478

A Randomized, Placebo Controlled and Double-blinded Study Assessing the Safety, Tolerability, Pharmacokinetics, and Efficacy of Subcutaneous Administrations of NNC0174 1213 in Male Participants With Overweight or Obesity.

ClinicalTrials.gov record

Registration

Registration: NCT06719011
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 178
Start: 2024-12-03
Primary completion: 2026-07-20
Lead sponsor: Novo Nordisk A/S
Conditions: Obesity; Overweight
Interventions: DRUG:NNC0174-1213 A; DRUG:Cagrilintide B; DRUG:Placebo A (NNC0174 1213 A)
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1308-5620

Registered primary outcomes

Part A: Number of treatment emergent adverse events (TEAE) reported by participants exposed to NNC0174 1213 [From NNC0174 1213 administration (Day 1) to completion of the end of study visit (Day 46)]
Part B: Number of treatment emergent adverse events (TEAE) [From first administration (Day 1) to completion of the end of study visit (Day 67)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.